Research Analysts Set Expectations for ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Stock analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Tuesday, May 20th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will post earnings of $1.57 per share for the year, up from their previous estimate of $1.53. HC Wainwright has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' FY2026 earnings at ($4.18) EPS, FY2027 earnings at ($3.26) EPS, FY2028 earnings at ($3.18) EPS and FY2029 earnings at ($1.28) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter last year, the company posted ($1.02) EPS.

Other equities analysts have also recently issued research reports about the company. Citigroup lowered their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. B. Riley reaffirmed a "buy" rating and set a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. Royal Bank of Canada reissued an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $42.13.

Arrowhead Pharmaceuticals Stock Down 6.0%

NASDAQ:ARWR opened at $15.31 on Thursday. The business's fifty day moving average price is $13.33 and its 200 day moving average price is $17.73. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -2.96 and a beta of 0.89. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $30.41.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,628 shares during the period. R Squared Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth about $38,000. GF Fund Management CO. LTD. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $49,000. Van ECK Associates Corp grew its holdings in Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,250 shares during the last quarter. Finally, CWM LLC grew its holdings in Arrowhead Pharmaceuticals by 134.3% in the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after buying an additional 2,523 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Christopher Richard Anzalone sold 40,322 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total value of $406,042.54. Following the completion of the sale, the chief executive officer now directly owns 4,022,055 shares in the company, valued at approximately $40,502,093.85. The trade was a 0.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders sold 275,880 shares of company stock worth $4,034,037. Corporate insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.